Latest News

Presentations at the 2026 ASCO Annual Meeting may reveal key advances in the use of different bispecific antibodies and CELMoDs in multiple myeloma care.

Nathan Goodyear, MD, explained why exercise must be treated as a precise, prescribable therapy in oncology to combat AEs and improve long-term survival.

Although colorectal cancer is not on the plenary stage at the 2026 ASCO Annual Meeting, there are still lots of high-profile trials reporting data.

Data from the phase 3 POTOMAC trial supported the FDA approval of durvalumab plus BCG in this non-muscle invasive bladder cancer population.

Enrollment for the WATER IV study evaluating aquablation vs radical prostatectomy has concluded, with primary end point results planned by spring 2027.

Sonikpreet Aulakh, MBBS, MD, discussed the shift toward multiomic personalization and tumor microenvironment reprogramming in neuro-oncology.

The FDA has assigned a Prescription Drug User Fee Act date of November 27, 2026, for neladalkib in this ALK-positive non–small cell lung cancer population.

Explore key insights on operationalizing bispecific antibodies in community oncology, outpatient step-up dosing, and shared staffing infrastructure.

The FDA extends camizestrant review. Plus, promising Bria-IMT survival data and a ctDNA blood test that spots breast cancer recurrence 4 years early.

Data from the phase 1/2 CADENZA trial support the approval of pivekimab sunirine for patients with blastic plasmacytoid dendritic cell neoplasms.

Orelabrutinib is now available in Australia for patients with relapsed/refractory mantle cell lymphoma.

The European Medicine Agency’s CHMP has adopted a positive opinion for encorafenib plus cetuximab and mFOLFOX6 in this treatment-naïve mCRC population.

Developers intend to submit a supplemental new drug application for toripalimab/chemotherapy in resectable stage II or III NSCLC.

Leading experts preview highly anticipated breast cancer data at ASCO 2026, including readouts from the SERENA-6, persevERA, and OPTIMA trials.

Host Brandon Mancini, MD, MBA, FACRO, discusses stereotactic radiosurgery, proton therapy, and other relevant modalities in the management of brain tumors.

Nathan Goodyear, MD, outlined how exercise and nutrition can counter treatment-induced immunosenescence and improve long-term oncology outcomes.

Findings from a cohort study demonstrated that coexposure to a COVID-19 mRNA vaccine within 90 days of anti–PD-(L)1 treatment improved OS in patients with cancer.

Approval of the FoundationOne CDx may help identify patients with NSCLC harboring MET exon 14 skipping alterations who are candidates for tepotinib.

Identifying patients early is key for getting them into the CAR T-cell therapy pipeline, according to Saad Z. Usmani, MD, MBA, FACP, FASCO.

Mitchell E. Horwitz, MD, discussed how omidubicel and other advances in allogeneic transplantation have impacted different hematologic oncology populations.

Nathan Goodyear, MD, discussed how structured exercise programs can reprogram the tumor immune microenvironment and enhance therapeutic efficacy.

Data from a phase 2 trial show that quizartinib plus omacetaxine mepesuccinate may better position patients to proceed to consolidative transplantation.